“…Since then, the TetR/Pip‐OFF system has been successfully used by several groups to study essential genes and validate drug targets in vitro and in vivo in different mycobacterial species (Serafini et al ., 2009, 2013; Cortes et al ., 2011; Di Luca et al ., 2012; Mondino et al ., 2013; Ventura et al ., 2013; Ahmed et al ., 2014, 2016; Bazet Lyonnet et al ., 2014; Bhowmick et al ., 2014; Boldrin et al ., 2014; Kolly et al ., 2014a,b; Pandey and Rodriguez, 2014; Verma and Chatterji, 2014; Gola et al ., 2015; Gupta et al ., 2015; Mori et al ., 2015; Hu et al ., 2016; Degiacomi et al ., 2017). This broad experience taught us that the main drawback of this otherwise very succesful system was the strength of the P ptr promoter, which causes overexpression of the gene of interest, when this is physiologically expressed at low level, with resulting accumulation of its product.…”